FDA Science Board Advisory Committee
Meeting
November 5, 2004
5630 Fishers Lane, Room 1066
8:00
a.m. Call to Order
Kenneth I. Shine,
M.D., Chair, FDA Science Board
Jan N.
Johannessen, Ph.D., Executive Secretary
8:10 a.m. Welcome and opening remarks
Lester
M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs
8:25
a.m. Update on the Critical Path
Initiative
CDER Critical Path
Activities
Douglas
Throckmorton, M.D., Center for Drug Evaluation and Research, FDA
CBER Critical
Path Activities
Jesse Goodman,
M.D., M.P.H., Director, Center for Biologics Evaluation and Research, FDA
CDRH Critical Path
Activities
Daniel Schultz,
M.D., Director, Center for Devices and Radiological Health, FDA
Overview of
Critical Path Docket Submissions
Lisa Rovin,
J.D., Director, Critical Path Initiative, Office of the Commissioner, FDA
9:30 a.m. Break
9:45 a.m. Critical
Path - Current Activities and The Path Forward
Janet Woodcock,
M.D., Acting Deputy Commissioner for Operations, FDA
10:15 a.m. Medical Technology Innovation Task
Force
Larry G. Kessler, Sc.D., Director, Office
of Science and Engineering Laboratories,
Center
for Devices and Radiological Health, FDA
10:45 a.m. Foods Critical Path
White Paper
Alan M. Rulis, Ph.D., Senior Advisor for
Special Projects, Center for Food Safety and Applied
Nutrition, FDA
11:00 a.m. Questions and Discussion with the
Board/Presenters
12:00 p.m. Lunch
1:00 p.m. Open Public Hearing
2:00 p.m. Pharmaceutical
cGMP Initiative
Janet
Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA
Ajaz Hussain,
Ph.D., Deputy Director, Office of Pharmaceutical Sciences, CDER, FDA
3:30 p.m. Break
3:45 p.m. ORA
Peer Review – Overview of Report and Plan for External Peer Review
John
R. Marzilli, Deputy Associate Commissioner for Regulatory Affairs, FDA
4:30 p.m. Questions and Discussion with
Board – Recommendations
5:00
p.m. Adjourn